Basics TG Therapeutics, Inc. TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of novel treatments for B-cell malignancies and autoimmune diseases. IPO Date: June 1, 2010 Sector: Healthcare Industry: Biotech Market Cap: $5.59B Activated in VL: True Average Daily Range Avg Daily Range: $0.45 | 3.15% Avg Daily Range (30 D): $0.53 | 1.54% Avg Daily Range (90 D): $0.56 | 1.65% Institutional Daily Volume Avg Daily Volume: 1.65M Avg Daily Volume (30 D): 1.48M Avg Daily Volume (90 D): 1.71M Trade Size Avg Trade Size (Sh.): 118 Avg Trade Size (Sh.) (30 D): 65 Avg Trade Size (Sh.) (90 D): 67 Institutional Trades Total Inst.Trades: 5,588 Avg Inst. Trade: $2.83M Avg Inst. Trade (30 D): $3.98M Avg Inst. Trade (90 D): $3.42M Avg Inst. Trade Volume: .15M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $4.94M Avg Closing Trade (30 D): $7.9M Avg Closing Trade (90 D): $8.12M Avg Closing Volume: 263.05K     News Aug 4, 2025 @ 4:23 PM TG Therapeutics Q2 Revenue Up 91% Source: Jesterai May 5, 2025 @ 11:00 AM TG Therapeutics Reports First Quarter 2025 Financi... Source: N/A Mar 9, 2025 @ 5:19 PM Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap G... Source: Lekha Gupta Nov 29, 2024 @ 1:00 PM TG Therapeutics to Participate in the Evercore Hea... Source: N/A Nov 21, 2024 @ 11:00 AM TG Therapeutics Ranked Number One Fastest-Growing ... Source: N/A Financials   TTM Q1 2025 Q4 2024 Basic EPS $.19 $.03 $.16 Diluted EPS $.17 $.03 $.15 Revenue $ 141.15M $ 120.86M $ 108.19M Gross Profit $ 122.21M $ 105.32M $ 92.79M Net Income / Loss $ 28.19M $ 5.06M $ 23.33M Operating Income / Loss $ 34.84M $ 8.62M $ 29.95M Cost of Revenue $ 18.94M $ 15.54M $ 15.4M Net Cash Flow $ -3M $ -47.75M $ -15.93M PE Ratio 198.12     Splits Apr 30, 2012:   5:281 Jul 14, 2011:   1:50 Sep 25, 2003:   1:5